In the future, pharmacological monitoring for ADAbs followed by optimization of the MTX dose in putative RA patients who may have a genetic predisposition rendering them prone to immunogenicity may lead to anti-TNF dose reductions in those achieving remission. This evidence concerns the gene TNF and rheumatoid arthritis.